GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OliX Pharmaceuticals Inc (XKRX:226950) » Definitions » EV-to-FCF

OliX Pharmaceuticals (XKRX:226950) EV-to-FCF

: -8.53 (As of Today)
View and export this data going back to 2018. Start your Free Trial

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, OliX Pharmaceuticals's Enterprise Value is ₩257,858 Mil. OliX Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-30,237 Mil. Therefore, OliX Pharmaceuticals's EV-to-FCF for today is -8.53.

The historical rank and industry rank for OliX Pharmaceuticals's EV-to-FCF or its related term are showing as below:

XKRX:226950' s EV-to-FCF Range Over the Past 10 Years
Min: -128.93   Med: -24.09   Max: -3.92
Current: -8.39

During the past 10 years, the highest EV-to-FCF of OliX Pharmaceuticals was -3.92. The lowest was -128.93. And the median was -24.09.

XKRX:226950's EV-to-FCF is ranked worse than
100% of 389 companies
in the Biotechnology industry
Industry Median: 4.27 vs XKRX:226950: -8.39

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-23), OliX Pharmaceuticals's stock price is ₩15240.00. OliX Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-1220.000. Therefore, OliX Pharmaceuticals's PE Ratio for today is At Loss.


OliX Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for OliX Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OliX Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.45 -127.55 -12.13 -7.91 -8.19

OliX Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.91 -8.78 -6.99 -7.71 -8.19

Competitive Comparison

For the Biotechnology subindustry, OliX Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OliX Pharmaceuticals EV-to-FCF Distribution

For the Biotechnology industry and Healthcare sector, OliX Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where OliX Pharmaceuticals's EV-to-FCF falls into.



OliX Pharmaceuticals EV-to-FCF Calculation

OliX Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=257858.310/-30236.65
=-8.53

OliX Pharmaceuticals's current Enterprise Value is ₩257,858 Mil.
OliX Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-30,237 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OliX Pharmaceuticals  (XKRX:226950) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

OliX Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=15240.00/-1220.000
=At Loss

OliX Pharmaceuticals's share price for today is ₩15240.00.
OliX Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-1220.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


OliX Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of OliX Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


OliX Pharmaceuticals (XKRX:226950) Business Description

Traded in Other Exchanges
N/A
Address
No. 1014 Gwanggyo Ace Tower 1, Daehak 4-ro, Yeongtong-gu, Gyeonggi, Suwon, KOR, 16226
OliX Pharmaceuticals Inc is a clinical stage biotechnology company. It is engaged in developing RNA interference (RNAi) technology therapeutics for dermal, ophthalmic and pulmonary diseases. The company's pipeline products include OLX101, OLX201, OLX301, OLX102, and others.

OliX Pharmaceuticals (XKRX:226950) Headlines

No Headlines